Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4065967 for the Treatment of Osteoarthritis
NCT07641517Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Countries
- 2
01
Overview
A Phase 2 trial of LY4065967 in osteoarthritis (OA), sponsored by Eli Lilly and Company. Started Jun 2026; status: recruiting.
02
Drugs
LY4065967
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07641517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641517.